{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000355","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.348254+00:00","generated_at":"2026-06-20T18:39:11.461586+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint prelim FY2022 net product revenue >$39.5M; Duker promoted to President & COO","bullets":["FY2022 net product revenue prelim >$39.5M, up from $35.3M in FY2021.","Cash and investments ~$144M as of Dec 31, 2022.","Jay Duker promoted to President & COO; base salary $581K, target bonus 55%, equity grants of 85K options and 45K RSUs.","Phase 2 DAVIO 2 (wet AMD) topline six-month data expected 4Q 2023; enrollment on track.","Phase 2 PAVIA (NPDR) enrollment completion expected by 4Q 2023; DME Phase 2 initiation planned 4Q 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000355","json":"https://secwatch.observer/filing/0000950170-23-000355.json","markdown":"https://secwatch.observer/filing/0000950170-23-000355.md","text":"https://secwatch.observer/filing/0000950170-23-000355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023000355/0000950170-23-000355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023000355/eypt-20230103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:39:11.461586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a5e188c4eeb60c964c4d422e6d5f01f937a3fee","claim":"EyePoint, Inc. reported full-year 2022 results: revenue exceed $39.5 million.","evidence_excerpt":"Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023000355/0000950170-23-000355-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"exceed $39.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"70ddb3a3cb","claim":"Jay S. Duker changed role as President and Chief Operating Officer at EyePoint, Inc..","evidence_excerpt":"Effective January 3, 2023 (the “Duker Start Date”), the Board of Directors (the “Board”) of the Company appointed Jay S. Duker, M.D., age 64, as the Company's President and Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023000355/0000950170-23-000355-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}